Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Glaucoma experts translate messages from NEI clinical trials
Chicago-In the late 1980s, ophthalmologists were challenged by Eddy and Billings to prove that IOP was an essential element in the management of primary open-angle glaucoma (POAG). Recent results from a number of National Eye Institute (NEI)-sponsored randomized controlled trials confirm that IOP reduction is effective in slowing both disease development and its progression. The results of those studies, however, have raised new issues in glaucoma management.
Related Videos
Related Content
